The payment will be made by Nov. 8, and it will resolve all disputes between Anacor and Valeant. That includes legal proceedings involving Medicis Pharma, which Valeant acquired in December. Anacor says that Dow Pharmaceutical Services, which is now part of Valeant, breached a contract related to Anacor's work on Jublia. The drug is a treatment for onychomycosis, a fungal infection of the nail and nail bed. Read the full story